国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

Mallinckrodt   
Covidien的制藥業務部Mallinckrodt提供用于疼痛及相關疾病診斷程序和治療的產品，是該領域垂直整合的領先企業。該公司是美國領先的鴉片類止痛藥供應商、活性藥物成份的領先制造商。該公司還是美國一家主要的醫用同位素锝-99m的供應商、放射藥品和造影劑及給藥系統的業界領導廠商。2012年銷售額為20億美元。
    

Mallinckrodt, the Pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions. We are the largest U.S. supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. We are also the largest global supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals, contrast media, and delivery systems. Mallinckrodt encompasses more than 5,500 dedicated employees around the globe, all focused on our core values of quality, integrity and service to meet the needs of patients globally.

Established as G. Mallinckrodt & Company in 1867, the $2 billion St. Louis-based business was acquired by Tyco International in 2000. In 2007, Tyco spun off its healthcare business into Covidien, a leading global healthcare products company. On December 15, 2011, Covidien announced plans to spin off Mallinckrodt as a standalone public company. The Company expects to complete the spin-off by mid-2013.

Mallinckrodt’s mission is to reveal and relieve disease for a healthier world, and our vision expands on our mission – a world made healthier by building on our heritage of distinctive capabilities to provide patients with pharmaceuticals that reveal and relieve disease.